CAIHL read · Jun 10, 2026
Dexcom RCT suggests CGM benefits for broad diabetes population
Framework
What CAIHL does
Critical AI Health Literacy (CAIHL) is an analytical lens — Hugo Campos and Liz Salmi's 2025 National Academy of Medicine commentary, "Critical AI Health Literacy as Liberation Technology." It applies Paulo Freire's theory of critical literacy to health AI.
The central question CAIHL asks is whose interests does this AI actually serve? Four dimensions answer it: who is the primary user, where is it hosted, whose interests does it advance, and does it expand or constrain patient agency.
This deep-read separates the four dimensions on a single item from the day's scan, so you can see the specific structural shape of the AI in question — not just the bucket it landed in.
The four dimensions
How this item reads through CAIHL
Primary user
patient
Patients, families, and care partners are the primary users of this AI.
Hosting
public
Hosted for public use (ChatGPT, Claude, consumer apps). Anyone with a device can use it.
Interests
mixed
Multiple stakeholder interests in tension; the alignment is not stable.
Agency
expanding
Expands patient capabilities, supports their questions, increases their ability to act on their own values across and beyond health systems.
Editor's CAIHL read
One-sentence synthesis
Trial evidence broadening CGM's patient population; expanding the longitudinal data surface that AI tools then consume.
In the scan
How this item appeared in the daily scan
Editor's note: The CGM is the wearable whose patient-level data has been most aggressively claimed for clinical use. If the indication broadens to non-insulin diabetes, the longitudinal-record surface the AI tools are being built against gets materially larger.
Summary: STAT: Dexcom-sponsored randomized trial suggests continuous glucose monitor benefits extend beyond insulin-using populations to the broader diabetes cohort — relevant for the wearable-to-clinic data pipeline that the AI tools then consume.
methodology
Limitations
CAIHL is a lens, not a verdict. The four dimensions are conditions of use — reassess them when a tool's business model, deployment context, or patient behavior changes. See the NAM commentary for the full framework.